Summary Table: Immune / Hematopoietic-Specific Promoters

Promoter	Target Cell Type	Size (bp)	Origin	Key Characteristics
CD11b	Myeloid cells	~250 bp – 1.7 kb	Human	Targets monocytes, macrophages, and granulocytes. A 250bp minimal version is often used for AAV.
CD68	Macrophages	~500 bp – 2.9 kb	Human	Highly specific for the monocyte/macrophage lineage. Often used to study inflammation or tumor-associated macrophages.
Lck	T cells	~500 bp – 3.2 kb	Mouse / Human	Derived from the lymphocyte-specific protein tyrosine kinase. Specific for T-lymphocytes.
CD19	B cells	~500 bp – 1.2 kb	Human	The classic marker for the B-cell lineage. Used to restrict expression to B-cells throughout their development.
F4/80 (Adgre1)	Macrophages	~1.0 kb – 2.5 kb	Mouse	The hallmark promoter for mature murine macrophages; widely used in rodent models of disease.

Insights into Immune-Targeted Vectors

1. T-Cell Targeting with Lck In the development of “in vivo” CAR-T therapies (where the virus is injected directly into the patient), the Lck promoter is crucial. It ensures that the Chimeric Antigen Receptor is only expressed on T cells, preventing “off-target” CAR expression in other tissues that could lead to systemic toxicity.

2. Macrophage Specificity (CD68 vs. F4/80) While CD68 is a standard macrophage marker, it can sometimes be expressed at low levels in other cell types (like dendritic cells). In mouse models, the F4/80 promoter is often considered more “mature macrophage-specific.” For human clinical applications, researchers frequently use a CD68 promoter modified with specific macrophage-responsive enhancers.

3. The Myeloid “Volume Knob” (CD11b) CD11b is highly useful because it is active in the entire myeloid branch. If you want to target both circulating monocytes and tissue-resident macrophages, CD11b is the preferred choice. Truncated versions (~250 bp) are especially valuable in AAV design because they leave significant room for complex payloads.

4. B-Cell Precision (CD19) The CD19 promoter is utilized when researchers want to turn B-cells into “protein factories” (similar to how the liver is used). Since B-cells circulate and can differentiate into long-lived plasma cells, a CD19-driven AAV can provide a steady supply of antibodies or enzymes.